abstract |
The present invention relates to an ADC of the following formula (I) in which Ab is an anti-IGF1R antibody characterized in that it comprises CDRs of the light chain of sequences SEQ ID Nos. 9, 5 and 11 respectively and heavy chain CDRs of sequence SEQ ID Nos 7, 2 and 3 respectively, and n is between 1 and 12, for its use in the treatment of proliferative diseases, such as cancer, characterized in that ADC is administered concomitantly or subsequently to docetaxel. |